Skip to Content
COVID-19 Resources
NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 01/25/17

Information below provided by the Pharmaceutical Company.

Bevacizumab (AVASTIN®)

Agent Description

A monoclonal antibody biologic that inhibits tumoral angiogenesis to suppress tumor growth.

Mechanism of Action

Anti-angiogenesis inhibitor.

Classification

Anti-angiogenesis inhibitor, anticancer agent, monoclonal antibody.

Molecular Targets

VEGF

Monograph

Approved in the US for colorectal cancer, NSCLC, RCC, GBM, ovarian cancer, cervical cancer.

Package insert: www.gene.com/download/pdf/avastin_prescribing.pdf External Link

Studies of Interest

Combinations with immunotherapeutic agents.

Information collaborator would like included in investigator proposals

N/A

Genentech supports non-clinical research proposals through a separate mechanism. Please visit https://www.gene.com/gene/reagents-program/reagents-program.jsp External Link if you wish to submit a request for a Genentech agent for non-clinical work.